Major roles of the circadian clock in cancer

References

1. 1.↵
   2. Shafi AA,
   3. Knudsen KE.

   Cancer and the circadian clock. Cancer Res. 2019; 79: 3806–14.

   OpenUrlCrossRef
2. 2.↵
   2. Ouyang Y,
   3. Andersson CR,
   4. Kondo T,
   5. Golden SS,
   6. Johnson CH.

   Resonating circadian clocks enhance fitness in cyanobacteria. Proc Natl Acad Sci U S A. 1998; 95: 8660–4.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   2. Turek FW.

   Circadian clocks: not your grandfather’s clock. Science. 2016; 354: 992–3.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   2. Mohawk JA,
   3. Green CB,
   4. Takahashi JS.

   Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012; 35: 445–62.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   2. Sancar A,
   3. van Gelder RN.

   Clocks, cancer, and chronochemotherapy. Science. 2021; 371: eabb0738.
6. 6.↵
   2. Partch CL,
   3. Green CB,
   4. Takahashi JS.

   Molecular architecture of the mammalian circadian clock. Trends Cell Biol. 2014; 24: 90–9.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   2. Patke A,
   3. Young MW,
   4. Axelrod S.

   Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol. 2020; 21: 67–84.

   OpenUrlPubMed
8. 8.
   2. Reppert SM,
   3. Weaver DR.

   Coordination of circadian timing in mammals. Nature. 2002; 418: 935–41.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.
   2. Hastings MH,
   3. Reddy AB,
   4. Maywood ES.

   A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003; 4: 649–61.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    2. Cederroth CR,
    3. Albrecht U,
    4. Bass J,
    5. Brown SA,
    6. Dyhrfjeld-Johnsen J,
    7. Gachon F, et al.

    Medicine in the fourth dimension. Cell Metab. 2019; 30: 238–50.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Lubov JE,
    3. Cvammen W,
    4. Kemp MG.

    The impact of the circadian clock on skin physiology and cancer development. Int J Mol Sci. 2021; 22: 6112.

    OpenUrl
12. 12.↵
    2. Kume K,
    3. Zylka MJ,
    4. Sriram S,
    5. Shearman LP,
    6. Weaver DR,
    7. Jin X, et al.

    mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell. 1999; 98: 193–205.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.
    2. Griffin EA,
    3. Staknis D,
    4. Weitz CJ.

    Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science. 1999; 286: 768–71.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    2. Sangoram AM,
    3. Saez L,
    4. Antoch MP,
    5. Gekakis N,
    6. Staknis D,
    7. Whiteley A, et al.

    Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron. 1998; 21: 1101–13.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    2. Narasimamurthy R,
    3. Virshup DM.

    The phosphorylation switch that regulates ticking of the circadian clock. Mol Cell 2021; 81: 1133–46.

    OpenUrlCrossRef
16. 16.
    2. Kondratov RV,
    3. Chernov MV,
    4. Kondratova AA,
    5. Gorbacheva VY,
    6. Gudkov AV,
    7. Antoch MP.

    BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev. 2003; 17: 1921–32.

    OpenUrlAbstract/FREE Full Text
17. 17.
    2. Kondratov RV,
    3. Shamanna RK,
    4. Kondratova AA,
    5. Gorbacheva VY,
    6. Antoch MP.

    Dual role of the CLOCK/BMAL1 circadian complex in transcriptional regulation. FASEB J. 2006; 20: 530–2.

    OpenUrlCrossRefPubMed
18. 18.
    2. Xu Y,
    3. Padiath QS,
    4. Shapiro RE,
    5. Jones CR,
    6. Wu SC,
    7. Saigoh N, et al.

    Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature. 2005; 434: 640–4.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.
    2. Etchegaray JP,
    3. Machida KK,
    4. Noton E,
    5. Constance CM,
    6. Dallmann R,
    7. Di Napoli MN, et al.

    Casein kinase 1 delta regulates the pace of the mammalian circadian clock. Mol Cell Biol. 2009; 29: 3853–66.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    2. Philpott JM,
    3. Narasimamurthy R,
    4. Ricci CG,
    5. Freeberg AM,
    6. Hunt SR,
    7. Yee LE, et al.

    Casein kinase 1 dynamics underlie substrate selectivity and the PER2 circadian phosphoswitch. Elife. 2020; 9: e52343.
21. 21.↵
    2. Green CB.

    Circadian posttranscriptional regulatory mechanisms in mammals. Cold Spring Harb Perspect Biol. 2018; 10: a030692.
22. 22.↵
    2. Shilts J,
    3. Chen G,
    4. Hughey JJ.

    Evidence for widespread dysregulation of circadian clock progression in human cancer. PeerJ. 2018; 6: e4327.
23. 23.↵
    2. Shostak A,
    3. Ruppert B,
    4. Ha N,
    5. Bruns P,
    6. Toprak UH,
    7. Eils R, et al.

    MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation. Nat Commun. 2016; 7: 11807.
24. 24.↵
    2. Huber AL,
    3. Papp SJ,
    4. Chan AB,
    5. Henriksson E,
    6. Jordan SD,
    7. Kriebs A, et al.

    CRY2 and FBXL3 cooperatively degrade c-MYC. Mol Cell. 2016; 64: 774–89.

    OpenUrlCrossRefPubMed
25. 25.↵
    2. Aviram R,
    3. Manella G,
    4. Kopelman N,
    5. Neufeld-Cohen A,
    6. Zwighaft Z,
    7. Elimelech M, et al.

    Lipidomics analyses reveal temporal and spatial lipid organization and uncover daily oscillations in intracellular organelles. Mol Cell 2016; 62: 636–48.

    OpenUrlCrossRefPubMed
26. 26.
    2. Blask DE,
    3. Dauchy RT,
    4. Dauchy EM,
    5. Mao L,
    6. Hill SM,
    7. Greene MW, et al.

    Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention. PLoS One. 2014; 9: e102776.
27. 27.
    2. Gamble KL,
    3. Berry R,
    4. Frank SJ,
    5. Young ME.

    Circadian clock control of endocrine factors. Nat Rev Endocrinol. 2014; 10: 466–75.

    OpenUrlCrossRefPubMed
28. 28.↵
    2. Greene MW.

    Circadian rhythms and tumor growth. Cancer Lett. 2012; 318: 115–23.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    2. He W,
    3. Holtkamp S,
    4. Hergenhan SM,
    5. Kraus K,
    6. de Juan A,
    7. Weber J, et al.

    Circadian expression of migratory factors establishes lineage-specific signatures that guide the homing of leukocyte subsets to tissues. Immunity. 2018; 49: 1175–90.e7.

    OpenUrl
30. 30.
    2. Aiello I,
    3. Fedele MLM,
    4. Román F,
    5. Marpegan L,
    6. Caldart C,
    7. Chiesa JJ, et al.

    Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. Sci Adv. 2020; 6: eaaz4530.
31. 31.
    2. Hadadi E,
    3. Taylor W,
    4. Li XM,
    5. Aslan Y,
    6. Villote M,
    7. Rivière J, et al.

    Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun. 2020; 11: 3193.

    OpenUrlCrossRefPubMed
32. 32.↵
    2. Wu Y,
    3. Tao B,
    4. Zhang T,
    5. Fan Y,
    6. Mao R.

    Pan-cancer analysis reveals disrupted circadian clock associates with T cell exhaustion. Front Immunol. 2019; 10: 2451.

    OpenUrl
33. 33.↵
    2. Thorsson V,
    3. Gibbs DL,
    4. Brown SD,
    5. Wolf D,
    6. Bortone DS,
    7. Ou Yang TH, et al.

    The immune landscape of cancer. Immunity. 2018; 48: 812–30.e14.

    OpenUrlCrossRefPubMed
34. 34.↵
    2. Xie Y,
    3. Tang Q,
    4. Chen G,
    5. Xie M,
    6. Yu S,
    7. Zhao J, et al.

    New insights into the circadian rhythm and its related diseases. Front Physiol. 2019; 10: 682.

    OpenUrl
35. 35.
    2. Leng Y,
    3. Musiek ES,
    4. Hu K,
    5. Cappuccio FP,
    6. Yaffe K.

    Association between circadian rhythms and neurodegenerative diseases. Lancet. Neurol. 2019; 18: 307–18.

    OpenUrl
36. 36.↵
    2. Kinouchi K,
    3. Sassone-Corsi P.

    Metabolic rivalry: circadian homeostasis and tumorigenesis. Nat Rev Cancer. 2020; 20: 645–61.

    OpenUrl
37. 37.
    2. Schibler U,
    3. Gotic I,
    4. Saini C,
    5. Gos P,
    6. Curie T,
    7. Emmenegger Y, et al.

    Clock-talk: interactions between central and peripheral circadian oscillators in mammals. Cold Spring Harb Symp Quant Biol. 2015; 80: 223–32.

    OpenUrlAbstract/FREE Full Text
38. 38.
    2. Cox KH,
    3. Takahashi JS.

    Circadian clock genes and the transcriptional architecture of the clock mechanism. J Mol Endocrinol. 2019; 63: R93–102.

    OpenUrlCrossRef
39. 39.↵
    2. Finger AM,
    3. Dibner C,
    4. Kramer A.

    Coupled network of the circadian clocks: a driving force of rhythmic physiology. FEBS Lett. 2020; 594: 2734–69.

    OpenUrlCrossRef
40. 40.↵
    2. Numata M,
    3. Hirano A,
    4. Yamamoto Y,
    5. Yasuda M,
    6. Miura N,
    7. Sayama K, et al.

    Metastasis of breast cancer promoted by circadian rhythm disruption due to light/dark shift and its prevention by dietary quercetin in mice. J Circadian Rhythms. 2021; 19: 2.

    OpenUrl
41. 41.
    2. Ha NH,
    3. Long J,
    4. Cai Q,
    5. Shu XO,
    6. Hunter KW.

    The circadian rhythm gene Arntl2 is a metastasis susceptibility gene for estrogen receptor-negative breast cancer. PLoS Genetics. 2016; 12: e1006267.
42. 42.
    2. Chen J,
    3. Liu A,
    4. Lin Z,
    5. Wang B,
    6. Chai X,
    7. Chen S, et al.

    Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κb signaling. Cancer Lett. 2020; 482: 56–71.

    OpenUrlPubMed
43. 43.↵
    2. Wang Y,
    3. Sun N,
    4. Lu C,
    5. Bei Y,
    6. Qian R,
    7. Hua L.

    Upregulation of circadian gene ‘hClock’ contribution to metastasis of colorectal cancer. Int J Oncol. 2017; 50: 2191–9.

    OpenUrl
44. 44.↵
    2. Koritala BSC,
    3. Porter KI,
    4. Arshad OA,
    5. Gajula RP,
    6. Mitchell HD,
    7. Arman T, et al.

    Night shift schedule causes circadian dysregulation of DNA repair genes and elevated DNA damage in humans. J Pineal Res. 2021; 70: e12726.
45. 45.
    2. Dun A,
    3. Zhao X,
    4. Jin X,
    5. Wei T,
    6. Gao X,
    7. Wang Y, et al.

    Association between night-shift work and cancer risk: updated systematic review and meta-analysis. Front Oncol. 2020; 10: 1006.

    OpenUrl
46. 46.↵
    2. Srour B,
    3. Plancoulaine S,
    4. Andreeva VA,
    5. Fassier P,
    6. Julia C,
    7. Galan P, et al.

    Circadian nutritional behaviours and cancer risk: new insights from the NutriNet-santé prospective cohort study: disclaimers. Int J Cancer. 2018; 143: 2369–79.

    OpenUrl
47. 47.↵
    2. Lou X,
    3. Wang H,
    4. Tu Y,
    5. Tan W,
    6. Jiang C,
    7. Sun J, et al.

    Alterations of sleep quality and circadian rhythm genes expression in elderly thyroid nodule patients and risks associated with thyroid malignancy. Sci Rep. 2021; 11: 13682.

    OpenUrl
48. 48.↵
    2. Kondratov RV,
    3. Kondratova AA,
    4. Gorbacheva VY,
    5. Vykhovanets OV,
    6. Antoch MP.

    Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev. 2006; 20: 1868–73.

    OpenUrlAbstract/FREE Full Text
49. 49.↵
    2. Yu EA,
    3. Weaver DR.

    Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging. 2011; 3: 479–93.

    OpenUrlCrossRefPubMedWeb of Science
50. 50.↵
    2. Papagiannakopoulos T,
    3. Bauer MR,
    4. Davidson SM,
    5. Heimann M,
    6. Subbaraj L,
    7. Bhutkar A, et al.

    Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 2016; 24: 324–31.

    OpenUrlCrossRefPubMed
51. 51.↵
    2. Sulli G,
    3. Lam MTY,
    4. Panda S.

    Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 2019; 5: 475–94.

    OpenUrl
52. 52.↵
    2. Zhou L,
    3. Luo Z,
    4. Li Z,
    5. Huang Q.

    Circadian clock is associated with tumor microenvironment in kidney renal clear cell carcinoma. Aging. 2020; 12: 14620–32.

    OpenUrl
53. 53.
    2. Yang Y,
    3. Yuan G,
    4. Xie H,
    5. Wei T,
    6. Zhu D,
    7. Cui J, et al.

    Circadian clock associates with tumor microenvironment in thoracic cancers. Aging. 2019; 11: 11814–28.

    OpenUrl
54. 54.
    2. Pavlova NN,
    3. Thompson CB.

    The emerging hallmarks of cancer metabolism. Cell Metab. 2016; 23: 27–47.

    OpenUrlCrossRefPubMed
55. 55.↵
    2. Chen WD,
    3. Wen MS,
    4. Shie SS,
    5. Lo YL,
    6. Wo HT,
    7. Wang CC, et al.

    The circadian rhythm controls telomeres and telomerase activity. Biochem Biophys Res Commun. 2014; 451: 408–14.

    OpenUrlCrossRefPubMed
56. 56.↵
    2. Ruan W,
    3. Yuan X,
    4. Eltzschig HK.

    Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021; 20: 287–307.

    OpenUrlCrossRef
57. 57.↵
    2. Chen P,
    3. Hsu WH,
    4. Han J,
    5. Xia Y,
    6. DePinho RA.

    Cancer stemness meets immunity: from mechanism to therapy. Cell Rep. 2021; 34: 108597.
58. 58.↵
    2. Chen P,
    3. Hsu WH,
    4. Chang A,
    5. Tan Z,
    6. Lan Z,
    7. Zhou A, et al.

    Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. Cancer Discov. 2020; 10: 371–81.

    OpenUrlAbstract/FREE Full Text
59. 59.
    2. Dong Z,
    3. Zhang G,
    4. Qu M,
    5. Gimple RC,
    6. Wu Q,
    7. Qiu Z, et al.

    Targeting glioblastoma stem cells through disruption of the circadian clock. Cancer Discov. 2019; 9: 1556–73.

    OpenUrlAbstract/FREE Full Text
60. 60.↵
    2. Puram RV,
    3. Kowalczyk MS,
    4. de Boer CG,
    5. Schneider RK,
    6. Miller PG,
    7. McConkey M, et al.

    Core circadian clock genes regulate leukemia stem cells in AML. Cell. 2016; 165: 303–16.

    OpenUrlCrossRefPubMed
61. 61.↵
    2. Hu Z,
    3. Brooks SA,
    4. Dormoy V,
    5. Hsu CW,
    6. Hsu HY,
    7. Lin LT, et al.

    Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis. 2015; 36 Suppl 1: S184–202.

    OpenUrlCrossRefPubMed
62. 62.
    2. Jiang X,
    3. Wang J,
    4. Deng X,
    5. Xiong F,
    6. Zhang S,
    7. Gong Z, et al.

    The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020; 39: 204.

    OpenUrl
63. 63.↵
    2. Hanahan D,
    3. Weinberg RA.

    Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74.

    OpenUrlCrossRefPubMedWeb of Science
64. 64.↵
    2. Shalapour S,
    3. Karin M.

    Pas de deux: control of anti-tumor immunity by cancer-associated inflammation. Immunity. 2019; 51: 15–26.

    OpenUrl
65. 65.↵
    2. Ramos CA,
    3. Ouyang C,
    4. Qi Y,
    5. Chung Y,
    6. Cheng CT,
    7. LaBarge MA, et al.

    A non-canonical function of BMAL1 metabolically limits obesity-promoted triple-negative breast cancer. iScience. 2020; 23: 100839.
66. 66.↵
    2. Matsunaga N,
    3. Ogino T,
    4. Hara Y,
    5. Tanaka T,
    6. Koyanagi S,
    7. Ohdo S.

    Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the antitumor effects of aldehyde dehydrogenase inhibitor. Cancer Res. 2018; 78: 3698–708.

    OpenUrlAbstract/FREE Full Text
67. 67.↵
    2. Chefetz I,
    3. Grimley E,
    4. Yang K,
    5. Hong L,
    6. Vinogradova EV,
    7. Suciu R, et al.

    A pan-ALDH1A inhibitor induces necroptosis in ovarian cancer stem-like cells. Cell Rep. 2019; 26: 3061–3075.e6.

    OpenUrl
68. 68.↵
    2. Kojima M,
    3. Hosoda H,
    4. Date Y,
    5. Nakazato M,
    6. Matsuo H,
    7. Kangawa K.

    Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656–60.

    OpenUrlCrossRefPubMedWeb of Science
69. 69.
    2. Avau B,
    3. Carbone F,
    4. Tack J,
    5. Depoortere I.

    Ghrelin signaling in the gut, its physiological properties, and therapeutic potential. Neurogastroenterol Motil. 2013; 25: 720–32.

    OpenUrlCrossRefPubMed
70. 70.↵
    2. Müller TD,
    3. Nogueiras R,
    4. Andermann ML,
    5. Andrews ZB,
    6. Anker SD,
    7. Argente J, et al.

    Ghrelin. Mol Metab. 2015; 4: 437–60.

    OpenUrl
71. 71.↵
    2. Waseem T,
    3. Javaid Ur R,
    4. Ahmad F,
    5. Azam M,
    6. Qureshi MA.

    Role of ghrelin axis in colorectal cancer: a novel association. Peptides. 2008; 29: 1369–76.

    OpenUrlPubMed
72. 72.
    2. Murata M,
    3. Okimura Y,
    4. Iida K,
    5. Matsumoto M,
    6. Sowa H,
    7. Kaji H, et al.

    Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem. 2002; 277: 5667–74.

    OpenUrlAbstract/FREE Full Text
73. 73.
    2. De Vriese C,
    3. Grégoire F,
    4. De Neef P,
    5. Robberecht P,
    6. Delporte C.

    Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. Endocrinology. 2005; 146: 1514–22.

    OpenUrlCrossRefPubMedWeb of Science
74. 74.
    2. Fung JNT,
    3. Seim I,
    4. Wang D,
    5. Obermair A,
    6. Chopin LK,
    7. Chen C.

    Expression and in vitro functions of the ghrelin axis in endometrial cancer. Horm Cancer. 2010; 1: 245–55.

    OpenUrlCrossRefPubMed
75. 75.↵
    2. Duxbury MS,
    3. Waseem T,
    4. Ito H,
    5. Robinson MK,
    6. Zinner MJ,
    7. Ashley SW, et al.

    Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun. 2003; 309: 464–68.

    OpenUrlCrossRefPubMedWeb of Science
76. 76.↵
    2. Lien GS,
    3. Lin CH,
    4. Yang YL,
    5. Wu MS,
    6. Chen BC.

    Ghrelin induces colon cancer cell proliferation through the GHS-R, Ras, PI3K, Akt, and mTOR signaling pathways. Eur J Pharmacol. 2016; 776: 124–31.

    OpenUrl
77. 77.↵
    2. Kraus D,
    3. Reckenbeil J,
    4. Wenghoefer M,
    5. Stark H,
    6. Frentzen M,
    7. Allam JP, et al.

    Ghrelin promotes oral tumor cell proliferation by modifying GLUT1 expression. Cell Mol Life Sci. 2016; 73: 1287–99.

    OpenUrl
78. 78.↵
    2. Díaz-Lezama N,
    3. Hernández-Elvira M,
    4. Sandoval A,
    5. Monroy A,
    6. Felix R,
    7. Monjaraz E.

    Ghrelin inhibits proliferation and increases T-type Ca2+ channel expression in PC-3 human prostate carcinoma cells. Biochem Biophys Res Commun. 2010; 403: 24–9.

    OpenUrlCrossRefPubMed
79. 79.↵
    2. Yeh AH,
    3. Jeffery PL,
    4. Duncan RP,
    5. Herington AC,
    6. Chopin LK.

    Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin Cancer Res. 2005; 11: 8295–303.

    OpenUrlAbstract/FREE Full Text
80. 80.↵
    2. Segers A,
    3. Desmet L,
    4. Sun S,
    5. Verbeke K,
    6. Tack J,
    7. Depoortere I.

    Night-time feeding of Bmal1-/- mice restores SCFA rhythms and their effect on ghrelin. J Endocrinol. 2020; 245: 155–64.

    OpenUrl
81. 81.↵
    2. Cummings DE,
    3. Purnell JQ,
    4. Frayo RS,
    5. Schmidova K,
    6. Wisse BE,
    7. Weigle DS.

    A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001; 50: 1714–9.

    OpenUrlAbstract/FREE Full Text
82. 82.
    2. Bodosi B,
    3. Gardi J,
    4. Hajdu I,
    5. Szentirmai E,
    6. Obal F,
    7. Krueger JM.

    Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 2004; 287: R1071–9.

    OpenUrlCrossRefPubMedWeb of Science
83. 83.↵
    2. Yildiz BO,
    3. Suchard MA,
    4. Wong ML,
    5. McCann SM,
    6. Licinio J.

    Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A. 2004; 101: 10434–9.

    OpenUrlAbstract/FREE Full Text
84. 84.↵
    2. Laermans J,
    3. Vancleef L,
    4. Tack J,
    5. Depoortere I.

    Role of the clock gene Bmal1 and the gastric ghrelin-secreting cell in the circadian regulation of the ghrelin-GOAT system. Sci Rep. 2015; 5: 16748.
85. 85.↵
    2. Diehl JA,
    3. Fuchs SY,
    4. Koumenis C.

    The cell biology of the unfolded protein response. Gastroenterology. 2011; 141: 38–41.

    OpenUrlCrossRefPubMedWeb of Science
86. 86.↵
    2. Bu Y,
    3. Yoshida A,
    4. Chitnis N,
    5. Altman BJ,
    6. Tameire F,
    7. Oran A, et al.

    A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nat Cell Biol. 2018; 20: 104–15.

    OpenUrlCrossRefPubMed
87. 87.↵
    2. Hart LS,
    3. Cunningham JT,
    4. Datta T,
    5. Dey S,
    6. Tameire F,
    7. Lehman SL, et al.

    ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest. 2012; 122: 4621–34.

    OpenUrlCrossRefPubMedWeb of Science
88. 88.↵
    2. Cramer T,
    3. Yamanishi Y,
    4. Clausen BE,
    5. Förster I,
    6. Pawlinski R,
    7. Mackman N, et al.

    HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003; 112: 645–57.

    OpenUrlCrossRefPubMedWeb of Science
89. 89.
    2. Masson N,
    3. Ratcliffe PJ.

    Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2014; 2: 3.

    OpenUrl
90. 90.↵
    2. Semenza GL,
    3. Roth PH,
    4. Fang HM,
    5. Wang GL.

    Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994; 269: 23757–63.

    OpenUrlAbstract/FREE Full Text
91. 91.↵
    2. Doedens AL,
    3. Stockmann C,
    4. Rubinstein MP,
    5. Liao D,
    6. Zhang N,
    7. DeNardo DG, et al.

    Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010; 70: 7465–75.

    OpenUrlAbstract/FREE Full Text
92. 92.↵
    2. Steggerda SM,
    3. Bennett MK,
    4. Chen J,
    5. Emberley E,
    6. Huang T,
    7. Janes JR, et al.

    Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017; 5: 101.

    OpenUrlAbstract/FREE Full Text
93. 93.↵
    2. Nguyen KD,
    3. Fentress SJ,
    4. Qiu Y,
    5. Yun K,
    6. Cox JS,
    7. Chawla A.

    Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science. 2013; 341: 1483–8.

    OpenUrlAbstract/FREE Full Text
94. 94.↵
    2. Alexander RK,
    3. Liou YH,
    4. Knudsen NH,
    5. Starost KA,
    6. Xu C,
    7. Hyde AL, et al.

    Bmal1 integrates mitochondrial metabolism and macrophage activation. ELife. 2020; 9: e54090.
95. 95.↵
    2. DeMarzo AM,
    3. Nelson WG,
    4. Isaacs WB,
    5. Epstein JI.

    Pathological and molecular aspects of prostate cancer. Lancet (London, England). 2003; 361: 955–64.

    OpenUrl
96. 96.
    2. Albihn A,
    3. Johnsen JI,
    4. Henriksson MA.

    MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163–224.

    OpenUrlCrossRefPubMed
97. 97.↵
    2. Fernandez PC,
    3. Frank SR,
    4. Wang L,
    5. Schroeder M,
    6. Liu S,
    7. Greene J, et al.

    Genomic targets of the human c-Myc protein. Genes Dev. 2003; 17: 1115–29.

    OpenUrlAbstract/FREE Full Text
98. 98.↵
    2. Adhikary S,
    3. Eilers M.

    Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6: 635–45.

    OpenUrlCrossRefPubMedWeb of Science
99. 99.↵
    2. Larsson LG,
    3. Henriksson MA.

    The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res. 2010; 316: 1429–37.

    OpenUrlCrossRefPubMedWeb of Science
100. 100.↵
     2. Altman BJ,
     3. Hsieh AL,
     4. Sengupta A,
     5. Krishnanaiah SY,
     6. Stine ZE,
     7. Walton ZE, et al.

     MYC disrupts the circadian clock and metabolism in cancer cells. Cell Metab. 2015; 22: 1009–19.

     OpenUrlCrossRefPubMed
101. 101.↵
     2. Gery S,
     3. Komatsu N,
     4. Baldjyan L,
     5. Yu A,
     6. Koo D,
     7. Koeffler HP.

     The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006; 22: 375–82.

     OpenUrlCrossRefPubMedWeb of Science
102. 102.
     2. Hua H,
     3. Wang Y,
     4. Wan C,
     5. Liu Y,
     6. Zhu B,
     7. Yang C, et al.

     Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 2006; 97: 589–96.

     OpenUrlCrossRefPubMed
103. 103.↵
     2. Yang X,
     3. Wood PA,
     4. Ansell CM,
     5. Quiton DFT,
     6. Oh EY,
     7. Du-Quiton J, et al.

     The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009; 26: 1323–39.

     OpenUrlCrossRefPubMed
104. 104.↵
     2. Repouskou A,
     3. Prombona A.

     c-MYC targets the central oscillator gene Per1 and is regulated by the circadian clock at the post-transcriptional level. Biochim Biophys Acta. 2016; 1859: 541–52.

     OpenUrl
105. 105.↵
     2. O’Connor K,
     3. Chen M.

     Dynamic functions of RhoA in tumor cell migration and invasion. Small GTPases. 2013; 4: 141–7.

     OpenUrlCrossRefPubMed
106. 106.↵
     2. Chiba S,
     3. Enami T,
     4. Ogawa S,
     5. Sakata-Yanagimoto M.

     G17V RHOA: Genetic evidence of GTP-unbound RHOA playing a role in tumorigenesis in T cells. Small GTPases. 2015; 6: 100–3.

     OpenUrl
107. 107.↵
     2. Nomikou E,
     3. Stournaras C,
     4. Kardassis D.

     Functional analysis of the promoters of the small GTPases RhoA and RhoB in embryonic stem cells. Biochem Biophys Res Commun. 2017; 491: 754–9.

     OpenUrl
108. 108.↵
     2. Ma TJ,
     3. Zhang ZW,
     4. Lu YL,
     5. Zhang YY,
     6. Tao DC,
     7. Liu YQ, et al.

     CLOCK and BMAL1 stabilize and activate RHOA to promote F-actin formation in cancer cells. Exp Mol Med. 2018; 50: 1–50.

     OpenUrlCrossRefPubMed
109. 109.↵
     2. Ramanathan C,
     3. Kathale ND,
     4. Liu D,
     5. Lee C,
     6. Freeman DA,
     7. Hogenesch JB, et al.

     mTOR signaling regulates central and peripheral circadian clock function. PLoS Genet. 2018; 14: e1007369.
110. 110.↵
     2. Memmott RM,
     3. Dennis PA.

     Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009; 21: 656–64.

     OpenUrlCrossRefPubMedWeb of Science
111. 111.↵
     2. Chiang GG,
     3. Abraham RT.

     Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007; 13: 433–42.

     OpenUrlCrossRefPubMedWeb of Science
112. 112.↵
     2. Alzahrani AS.

     PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019; 59: 125–32.

     OpenUrlCrossRefPubMed
113. 113.↵
     2. Hardie DG.

     AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007; 8: 774–85.

     OpenUrlCrossRefPubMedWeb of Science
114. 114.↵
     2. Lee Y,
     3. Kim EK.

     AMP-activated protein kinase as a key molecular link between metabolism and clockwork. Exp Mol Med. 2013; 45: e33.
115. 115.↵
     2. Um JH,
     3. Yang S,
     4. Yamazaki S,
     5. Kang H,
     6. Viollet B,
     7. Foretz M, et al.

     Activation of 5’-AMP-activated kinase with diabetes drug metformin induces casein kinase Iepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. J Biol Chem. 2007; 282: 20794–8.

     OpenUrlAbstract/FREE Full Text
116. 116.↵
     2. Liang J,
     3. Mills GB.

     AMPK: a contextual oncogene or tumor suppressor? Cancer Res. 2013; 73: 2929–35.

     OpenUrlAbstract/FREE Full Text
117. 117.↵
     2. Carling D.

     AMPK signalling in health and disease. Curr Opin Cell Biol. 2017; 45: 31–7.

     OpenUrlCrossRefPubMed
118. 118.↵
     2. Li Q,
     3. Xia D,
     4. Wang Z,
     5. Liu B,
     6. Zhang J,
     7. Peng P, et al.

     Circadian rhythm gene PER3 negatively regulates stemness of prostate cancer stem cells via WNT/β-catenin signaling in tumor microenvironment. Front Cell Dev Biol. 2021; 9: 656981.
119. 119.↵
     2. Maiese K.

     Moving to the rhythm with clock (Circadian) genes, autophagy, mTOR, and SIRT1 in degenerative disease and cancer. Curr Neurovasc Res. 2017; 14: 299–304.

     OpenUrlCrossRef
120. 120.↵
     2. Okazaki F,
     3. Matsunaga N,
     4. Okazaki H,
     5. Azuma H,
     6. Hamamura K,
     7. Tsuruta A, et al.

     Circadian clock in a mouse colon tumor regulates intracellular iron levels to promote tumor progression. J Biol Chem. 2016; 291: 7017–28.

     OpenUrlAbstract/FREE Full Text
121. 121.↵
     2. Shen Y,
     3. Endale M,
     4. Wang W,
     5. Morris AR,
     6. Francey LJ,
     7. Harold RL, et al.

     NF-κB modifies the mammalian circadian clock through interaction with the core clock protein BMAL1. PLoS Genet. 2021; 17: e1009933.
122. 122.
     2. Kubra S,
     3. Zhang H,
     4. Si Y,
     5. Gao X,
     6. Wang T,
     7. Pan L, et al.

     REGγ regulates circadian clock by modulating BMAL1 protein stability. Cell Death Discov. 2021; 7: 335.

     OpenUrl
123. 123.
     2. Moreno-Smith M,
     3. Milazzo G,
     4. Tao L,
     5. Fekry B,
     6. Zhu B,
     7. Mohammad MA, et al.

     Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021; 12: 4006.

     OpenUrlCrossRef
124. 124.↵
     2. Jiang W,
     3. Zhao S,
     4. Jiang X,
     5. Zhang E,
     6. Hu G,
     7. Hu B, et al.

     The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett. 2016; 371: 314–25.

     OpenUrlCrossRefPubMed
125. 125.↵
     2. Liu L,
     3. Liao JZ,
     4. He XX,
     5. Li PY.

     The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget. 2017; 8: 57707–22.

     OpenUrlCrossRef
126. 126.↵
     2. Torre LA,
     3. Bray F,
     4. Siegel RL,
     5. Ferlay J,
     6. Lortet-Tieulent J,
     7. Jemal A.

     Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87–108.

     OpenUrlCrossRefPubMed
127. 127.↵
     World Health Organization, Projections of Mortality and Causes of Death, 2016 to 2060. Geneva, Switzerland: World Health Organization; 2020.
128. 128.↵
     2. Singal AG,
     3. El-Serag HB.

     Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015; 13: 2140–51.

     OpenUrlCrossRefPubMed
129. 129.↵
     2. Fattovich G,
     3. Stroffolini T,
     4. Zagni I,
     5. Donato F.

     Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127(5 Suppl 1): S35–50.

     OpenUrlCrossRefPubMedWeb of Science
130. 130.↵
     2. Molina-Aguilar C,
     3. Guerrero-Carrillo MdJ,
     4. Espinosa-Aguirre JJ,
     5. Olguin-Reyes S,
     6. Castro-Belio T,
     7. Vázquez-Martínez O, et al.

     Time-caloric restriction inhibits the neoplastic transformation of cirrhotic liver in rats treated with diethylnitrosamine. Carcinogenesis. 2017; 38: 847–58.

     OpenUrl
131. 131.↵
     2. Krizkova S,
     3. Kepinska M,
     4. Emri G,
     5. Rodrigo MAM,
     6. Tmejova K,
     7. Nerudova D, et al.

     Microarray analysis of metallothioneins in human diseases--A review. J Pharm Biomed Anal, 2016; 117: 464–73.

     OpenUrl
132. 132.
     2. Fujie T,
     3. Segawa Y,
     4. Yoshida E,
     5. Kimura T,
     6. Fujiwara Y,
     7. Yamamoto C, et al.

     Induction of metallothionein isoforms by copper diethyldithiocarbamate in cultured vascular endothelial cells. J Toxicol Sci. 2016; 41: 225–32.

     OpenUrl
133. 133.↵
     2. Klaassen CD,
     3. Liu J,
     4. Choudhuri S.

     Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. 1999; 39: 267–94.

     OpenUrlCrossRefPubMedWeb of Science
134. 134.↵
     2. Li H,
     3. Lu YF,
     4. Chen H,
     5. Liu J.

     Dysregulation of metallothionein and circadian genes in human hepatocellular carcinoma. Chronobiol Int. 2017; 34: 192–202.

     OpenUrl
135. 135.↵
     2. Hill SM,
     3. Belancio VP,
     4. Dauchy RT,
     5. Xiang S,
     6. Brimer S,
     7. Mao L, et al.

     Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015; 22: R183–204.

     OpenUrlAbstract/FREE Full Text
136. 136.
     2. Reiter RJ,
     3. Rosales-Corral SA,
     4. Tan DX,
     5. Acuna-Castroviejo D,
     6. Qin L,
     7. Yang SF, et al.

     Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci. 2017; 18: 843.

     OpenUrl
137. 137.↵
     2. Li Y,
     3. Li S,
     4. Zhou Y,
     5. Meng X,
     6. Zhang JJ,
     7. Xu DP, et al.

     Melatonin for the prevention and treatment of cancer. Oncotarget. 2017; 8: 39896–921.

     OpenUrlPubMed
138. 138.↵
     2. Sánchez DI,
     3. González-Fernández B,
     4. Crespo I,
     5. San-Miguel B,
     6. Álvarez M,
     7. González-Gallego J, et al.

     Melatonin modulates dysregulated circadian clocks in mice with diethylnitrosamine-induced hepatocellular carcinoma. J Pineal Res. 2018; 65: e12506.
139. 139.↵
     2. Sladek FM,
     3. Zhong WM,
     4. Lai E,
     5. Darnell JE.

     Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 1990; 4: 2353–65.

     OpenUrlAbstract/FREE Full Text
140. 140.↵
     2. Battle MA,
     3. Konopka G,
     4. Parviz F,
     5. Gaggl AL,
     6. Yang C,
     7. Sladek FM, et al.

     Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A. 2006; 103: 8419–24.

     OpenUrlAbstract/FREE Full Text
141. 141.↵
     2. Bonzo JA,
     3. Ferry CH,
     4. Matsubara T,
     5. Kim JH,
     6. Gonzalez FJ.

     Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem. 2012; 287: 7345–56.

     OpenUrlAbstract/FREE Full Text
142. 142.↵
     2. Chellappa K,
     3. Deol P,
     4. Evans JR,
     5. Vuong LM,
     6. Chen G,
     7. Briançon N, et al.

     Opposing roles of nuclear receptor HNF4α isoforms in colitis and colitis-associated colon cancer. ELife. 2016; 5: e10903.
143. 143.
     2. Walesky C,
     3. Apte U.

     Role of hepatocyte nuclear factor 4α (HNF4α) in cell proliferation and cancer. Gene Expr. 2015; 16: 101–8.

     OpenUrlCrossRefPubMed
144. 144.
     2. Vuong LM,
     3. Chellappa K,
     4. Dhahbi JM,
     5. Deans JR,
     6. Fang B,
     7. Bolotin E, et al.

     Differential effects of hepatocyte nuclear factor 4α isoforms on tumor growth and T-cell factor 4/AP-1 interactions in human colorectal cancer cells. Mol Cell Biol. 2015; 35: 3471–90.

     OpenUrlAbstract/FREE Full Text
145. 145.↵
     2. Ning BF,
     3. Ding J,
     4. Yin C,
     5. Zhong W,
     6. Wu K,
     7. Zeng X, et al.

     Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res. 2010; 70: 7640–51.

     OpenUrlAbstract/FREE Full Text
146. 146.↵
     2. Hatziapostolou M,
     3. Polytarchou C,
     4. Aggelidou E,
     5. Drakaki A,
     6. Poultsides GA,
     7. Jaeger SA, et al.

     An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011; 147: 1233–47.

     OpenUrlCrossRefPubMedWeb of Science
147. 147.↵
     2. Walesky C,
     3. Edwards G,
     4. Borude P,
     5. Gunewardena S,
     6. O’Neil M,
     7. Yoo B, et al.

     Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology. 2013; 57: 2480–90.

     OpenUrlCrossRefPubMedWeb of Science
148. 148.↵
     2. Tanaka T,
     3. Jiang S,
     4. Hotta H,
     5. Takano K,
     6. Iwanari H,
     7. Sumi K, et al.

     Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol. 2006; 208: 662–72.

     OpenUrlCrossRefPubMedWeb of Science
149. 149.↵
     2. Chellappa K,
     3. Jankova L,
     4. Schnabl JM,
     5. Pan S,
     6. Brelivet Y,
     7. Fung CLS, et al.

     Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer. Proc Natl Acad Sci U S A. 2012; 109: 2302–7.

     OpenUrlAbstract/FREE Full Text
150. 150.↵
     2. Fekry B,
     3. Ribas-Latre A,
     4. Baumgartner C,
     5. Deans JR,
     6. Kwok C,
     7. Patel P, et al.

     Incompatibility of the circadian protein BMAL1 and HNF4α in hepatocellular carcinoma. Nat Commun. 2018; 9: 4349.

     OpenUrlCrossRef
151. 151.↵
     2. Biller LH,
     3. Schrag D.

     Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021; 325: 669–85.

     OpenUrlCrossRefPubMed
152. 152.
     2. Sung H,
     3. Ferlay J,
     4. Siegel RL,
     5. Laversanne M,
     6. Soerjomataram I,
     7. Jemal A, et al.

     Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49.

     OpenUrlCrossRefPubMed
153. 153.↵
     2. Siegel RL,
     3. Medhanie GA,
     4. Fedewa SA,
     5. Jemal A.

     State variation in early-onset colorectal cancer in the United States, 1995-2015. J Natl Cancer Inst. 2019; 111: 1104–6.

     OpenUrl
154. 154.↵
     2. Zhang Y,
     3. Devocelle A,
     4. Souza L,
     5. Foudi A,
     6. Tenreira Bento S,
     7. Desterke C, et al.

     BMAL1 knockdown triggers different colon carcinoma cell fates by altering the delicate equilibrium between AKT/mTOR and P53/P21 pathways. Aging. 2020; 12: 8067–83.

     OpenUrl
155. 155.↵
     2. Stokes K,
     3. Nunes M,
     4. Trombley C,
     5. Flôres DEFL,
     6. Wu G,
     7. Taleb Z, et al.

     The circadian clock gene, Bmal1, regulates intestinal stem cell signaling and represses tumor initiation. Cell Mol Gastroenterol Hepatol. 2021; 12: 1847–72.

     OpenUrl
156. 156.↵
     2. Liu JL,
     3. Wang CY,
     4. Cheng TY,
     5. Rixiati Y,
     6. Ji C,
     7. Deng M, et al.

     Circadian clock disruption suppresses PDL1 intraepithelial B cells in experimental colitis and colitis-associated colorectal cancer. Cell Mol Gastroenterol Hepatol. 2021; 12: 251–76.

     OpenUrl
157. 157.↵
     2. Zhang Y,
     3. Ma J,
     4. Zhang S,
     5. Deng G,
     6. Wu X,
     7. He J, et al.

     A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis. 2015; 30: 1173–83.

     OpenUrlCrossRef
158. 158.↵
     2. Huisman SA,
     3. Oklejewicz M,
     4. Ahmadi AR,
     5. Tamanini F,
     6. Ijzermans JNM,
     7. van der Horst GTJ, et al.

     Colorectal liver metastases with a disrupted circadian rhythm phase shift the peripheral clock in liver and kidney. Int J Cancer. 2015; 136: 1024–32.

     OpenUrlPubMed
159. 159.↵
     2. Dong P,
     3. Wang Y,
     4. Liu Y,
     5. Zhu C,
     6. Lin J,
     7. Qian R, et al.

     BMAL1 induces colorectal cancer metastasis by stimulating exosome secretion. Mol Biol Rep. 2022; 49: 373–84.

     OpenUrl
160. 160.↵
     2. Siegel RL,
     3. Miller KD,
     4. Jemal A.

     Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30.

     OpenUrlCrossRefPubMed
161. 161.↵
     2. Dai X,
     3. Li T,
     4. Bai Z,
     5. Yang Y,
     6. Liu X,
     7. Zhan J, et al.

     Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015; 5: 2929–43.

     OpenUrlCrossRefPubMed
162. 162.↵
     2. Xiang S,
     3. Mao L,
     4. Duplessis T,
     5. Yuan L,
     6. Dauchy R,
     7. Dauchy E, et al.

     Oscillation of clock and clock controlled genes induced by serum shock in human breast epithelial and breast cancer cells: regulation by melatonin. Breast Cancer (Auckl). 2012; 6: 137–50.

     OpenUrlCrossRefPubMed
163. 163.↵
     2. Rossetti S,
     3. Esposito J,
     4. Corlazzoli F,
     5. Gregorski A,
     6. Sacchi N.

     Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes. Cell Cycle. 2012; 11: 350–60.

     OpenUrlCrossRefPubMed
164. 164.↵
     2. Lesicka M,
     3. Jabłońska E,
     4. Wieczorek E,
     5. Seroczyńska B,
     6. Siekierzycka A,
     7. Skokowski J, et al.

     Altered circadian genes expression in breast cancer tissue according to the clinical characteristics. PLoS One. 2018; 13: e0199622.
165. 165.↵
     2. Broadberry E,
     3. McConnell J,
     4. Williams J,
     5. Yang N,
     6. Zindy E,
     7. Leek A, et al.

     Disrupted circadian clocks and altered tissue mechanics in primary human breast tumours. Breast Cancer Res. 2018; 20: 125.

     OpenUrl
166. 166.↵
     2. Korkmaz T,
     3. Aygenli F,
     4. Emisoglu H,
     5. Ozcelik G,
     6. Canturk A,
     7. Yilmaz S, et al.

     Opposite carcinogenic effects of circadian clock gene BMAL1. Sci Rep. 2018; 8: 16023.

     OpenUrlCrossRefPubMed
167. 167.↵
     2. Kwon YJ,
     3. Seo EB,
     4. Kwon SH,
     5. Lee SH,
     6. Kim SK,
     7. Park SK, et al.

     Extracellular Acidosis Promotes Metastatic Potency via Decrease of the BMAL1 Circadian Clock Gene in Breast Cancer. Cells. 2020; 9: 989.

     OpenUrl
168. 168.↵
     2. Sharma D,
     3. Kumar S,
     4. Narasimhan B.

     Estrogen alpha receptor antagonists for the treatment of breast cancer: a review. Chem Cent J. 2018; 12: 107.

     OpenUrl
169. 169.↵
     2. Xie F,
     3. Wang L,
     4. Liu Y,
     5. Liu Z,
     6. Zhang Z,
     7. Pei J, et al.

     ASMT regulates tumor metastasis through the circadian clock system in triple-negative breast cancer. Front Oncol. 2020; 10: 537247.
170. 170.↵
     2. Boese AC,
     3. Kang S.

     Tumor progression of breast cancer during hyperinsulinemic obesity. Trends Mol Med. 2020; 26: 354–6.

     OpenUrl
171. 171.↵
     2. Hambardzumyan D,
     3. Gutmann DH,
     4. Kettenmann H.

     The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016; 19: 20–7.

     OpenUrlCrossRefPubMed
172. 172.↵
     2. Mantovani A,
     3. Sica A,
     4. Sozzani S,
     5. Allavena P,
     6. Vecchi A,
     7. Locati M.

     The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677–86.

     OpenUrlCrossRefPubMedWeb of Science
173. 173.
     2. Verreck FAW,
     3. de Boer T,
     4. Langenberg DML,
     5. Hoeve MA,
     6. Kramer M,
     7. Vaisberg E, et al.

     Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 2004; 101: 4560–5.

     OpenUrlAbstract/FREE Full Text
174. 174.↵
     2. Qin C,
     3. Zhou LQ,
     4. Ma XT,
     5. Hu ZW,
     6. Yang S,
     7. Chen M, et al.

     Dual functions of microglia in ischemic stroke. Neurosci Bull. 2019; 35: 921–33.

     OpenUrlPubMed
175. 175.↵
     2. Li X,
     3. Guan J,
     4. Jiang Z,
     5. Cheng S,
     6. Hou W,
     7. Yao J, et al.

     Microglial exosome miR-7239-3p promotes glioma progression by regulating circadian genes. Neurosci Bull. 2021; 37: 497–510.

     OpenUrl
176. 176.↵
     2. de Assis LVM,
     3. Mendes D,
     4. Silva MM,
     5. Kinker GS,
     6. Pereira-Lima I,
     7. Moraes MN, et al.

     Melanopsin mediates UVA-dependent modulation of proliferation, pigmentation, apoptosis, and molecular clock in normal and malignant melanocytes. Biochim Biophys Acta Mol Cell Res. 2020; 1867: 118789.
177. 177.↵
     2. de Assis LVM,
     3. Moraes MN,
     4. da Silveira Cruz-Machado S,
     5. Castrucci AML.

     The effect of white light on normal and malignant murine melanocytes: a link between opsins, clock genes, and melanogenesis. Biochim Biophys Acta. 2016; 1863: 1119–33.

     OpenUrl
178. 178.↵
     2. Zhanfeng N,
     3. Yanhui L,
     4. Zhou F,
     5. Shaocai H,
     6. Guangxing L,
     7. Hechun X.

     Circadian genes Per1 and Per2 increase radiosensitivity of glioma in vivo. Oncotarget 2015; 6: 9951–8.

     OpenUrlCrossRef
179. 179.
     2. Shen H,
     3. Cook K,
     4. Gee HE,
     5. Hau E.

     Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas. J Exp Clin Cancer Res CR. 2020; 39: 129.

     OpenUrl
180. 180.
     2. Wagner PM,
     3. Prucca CG,
     4. Velazquez FN,
     5. Sosa Alderete LG,
     6. Caputto BL,
     7. Guido ME.

     Temporal regulation of tumor growth in nocturnal mammals: in vivo studies and chemotherapeutical potential. FASEB J. 2021; 35: e21231.
181. 181.↵
     2. Katamune C,
     3. Koyanagi S,
     4. Hashikawa KI,
     5. Kusunose N,
     6. Akamine T,
     7. Matsunaga N, et al.

     Mutation of the gene encoding the circadian clock component PERIOD2 in oncogenic cells confers chemoresistance by up-regulating the Aldh3a1 gene. J Biol Chem. 2019; 294: 547–58.

     OpenUrlAbstract/FREE Full Text
182. 182.↵
     2. Ferrara N,
     3. Hillan KJ,
     4. Gerber HP,
     5. Novotny W.

     Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391–400.

     OpenUrlCrossRefPubMedWeb of Science
183. 183.↵
     2. De Palma M,
     3. Biziato D,
     4. Petrova TV.

     Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017; 17: 457–74.

     OpenUrlCrossRefPubMed
184. 184.↵
     2. Koyanagi S,
     3. Kuramoto Y,
     4. Nakagawa H,
     5. Aramaki H,
     6. Ohdo S,
     7. Soeda S, et al.

     A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003; 63: 7277–83.

     OpenUrlAbstract/FREE Full Text
185. 185.
     2. Peek CB,
     3. Levine DC,
     4. Cedernaes J,
     5. Taguchi A,
     6. Kobayashi Y,
     7. Tsai SJ, et al.

     Circadian clock interaction with HIF1α mediates oxygenic metabolism and anaerobic glycolysis in skeletal muscle. Cell Metabolism. 2017; 25: 86–92.

     OpenUrl
186. 186.↵
     2. Ma Z,
     3. Jin X,
     4. Qian Z,
     5. Li F,
     6. Xu M,
     7. Zhang Y, et al.

     Deletion of clock gene Bmal1 impaired the chondrocyte function due to disruption of the HIF1α-VEGF signaling pathway. Cell Cycle. 2019; 18: 1473–89.

     OpenUrl
187. 187.↵
     2. Burgermeister E,
     3. Battaglin F,
     4. Eladly F,
     5. Wu W,
     6. Herweck F,
     7. Schulte N, et al.

     Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine. 2019; 45: 139–54.

     OpenUrl
188. 188.↵
     2. Thiery JP,
     3. Acloque H,
     4. Huang RYJ,
     5. Nieto MA.

     Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139: 871–90.

     OpenUrlCrossRefPubMedWeb of Science
189. 189.↵
     2. Zhang J,
     3. Tian XJ,
     4. Xing J.

     Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks. J Clin Med. 2016; 5: 41.

     OpenUrl
190. 190.↵
     2. Jeanes A,
     3. Gottardi CJ,
     4. Yap AS.

     Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008; 27: 6920–9.

     OpenUrlCrossRefPubMedWeb of Science
191. 191.↵
     2. Zhang Y,
     3. Devocelle A,
     4. Desterke C,
     5. de Souza LEB,
     6. Hadadi É,
     7. Acloque H, et al.

     BMAL1 knockdown leans epithelial-mesenchymal balance toward epithelial properties and decreases the chemoresistance of colon carcinoma cells. Int J Mol Sci. 2021; 22: 5247.

     OpenUrl
192. 192.↵
     2. Slat EA,
     3. Sponagel J,
     4. Marpegan L,
     5. Simon T,
     6. Kfoury N,
     7. Kim A, et al.

     Cell-intrinsic, Bmal1-dependent circadian regulation of temozolomide sensitivity in glioblastoma. J Biol Rhythms. 2017; 32: 121–9.

     OpenUrlCrossRef
193. 193.↵
     2. Wagner PM,
     3. Sosa Alderete LG,
     4. Gorné LD,
     5. Gaveglio V,
     6. Salvador G,
     7. Pasquaré S, et al.

     Proliferative glioblastoma cancer cells exhibit persisting temporal control of metabolism and display differential temporal drug susceptibility in chemotherapy. Mol Neurobiol. 2019; 56: 1276–92.

     OpenUrl
194. 194.↵
     2. Jiang W,
     3. Zhao S,
     4. Shen J,
     5. Guo L,
     6. Sun Y,
     7. Zhu Y, et al.

     The MiR-135b-BMAL1-YY1 loop disturbs pancreatic clockwork to promote tumourigenesis and chemoresistance. Cell Death Dis. 2018; 9: 149.

     OpenUrlCrossRef
195. 195.↵
     2. Tang Q,
     3. Cheng B,
     4. Xie M,
     5. Chen Y,
     6. Zhao J,
     7. Zhou X, et al.

     Circadian clock gene Bmal1 inhibits tumorigenesis and increases paclitaxel sensitivity in tongue squamous cell carcinoma. Cancer Res. 2017; 77: 532–44.

     OpenUrlAbstract/FREE Full Text
196. 196.↵
     2. Trebucq LL,
     3. Cardama GA,
     4. Lorenzano Menna P,
     5. Golombek DA,
     6. Chiesa JJ,
     7. Marpegan L.

     Timing of novel drug 1A-116 to circadian rhythms improves therapeutic effects against glioblastoma. Pharmaceutics. 2021; 13: 1091.

     OpenUrl
197. 197.↵
     2. Cardama GA,
     3. Gonzalez N,
     4. Ciarlantini M,
     5. Gandolfi Donadío L,
     6. Comin MJ,
     7. Alonso DF, et al.

     Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. OncoTargets and Therapy, 2014; 7: 2021–33.

     OpenUrl
198. 198.
     2. Cabrera M,
     3. Echeverria E,
     4. Lenicov FR,
     5. Cardama G,
     6. Gonzalez N,
     7. Davio C, et al.

     Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget, 2017; 8: 98509–23.

     OpenUrl
199. 199.
     2. Parri M,
     3. Chiarugi P.

     Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. 2010; 8: 23.

     OpenUrlCrossRefPubMed
200. 200.↵
     2. Ridley AJ.

     Rho GTPase signalling in cell migration. Curr Opin Cell Biol. 2015; 36: 103–12.

     OpenUrlCrossRefPubMed
201. 201.↵
     2. Teixeira AAS,
     3. Biondo LA,
     4. Silveira LS,
     5. Lima EA,
     6. Batatinha HA,
     7. Diniz TA, et al.

     Doxorubicin modulated clock genes and cytokines in macrophages extracted from tumor-bearing mice. Cancer Biol Ther. 2020; 21: 344–53.

     OpenUrl
202. 202.↵
     2. Mendes MCS,
     3. Pimentel GD,
     4. Costa FO,
     5. Carvalheira JBC.

     Molecular and neuroendocrine mechanisms of cancer cachexia. J Endocrinol. 2015; 226: R29–43.

     OpenUrlAbstract/FREE Full Text
203. 203.
     2. Kinsey E,
     3. Ajazi E,
     4. Wang X,
     5. Johnston MAM,
     6. Crawford J.

     Predictors of physical and functional loss in advanced-stage lung cancer patients receiving platinum chemotherapy. J Thorac Oncol. 2018; 13: 1294–301.

     OpenUrl
204. 204.↵
     2. Muliawati Y,
     3. Haroen H,
     4. Rotty LWA.

     Cancer anorexia - cachexia syndrome. Acta Med Indones. 2012; 44: 154–62.

     OpenUrlPubMed
205. 205.↵
     2. von Haehling S,
     3. Anker SD.

     Cachexia as major underestimated unmet medical need: facts and numbers. Int J Cardiol. 2012; 161: 121–3.

     OpenUrlCrossRefPubMed
206. 206.↵
     2. Colldén G,
     3. Tschöp MH,
     4. Müller TD.

     Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci. 2017; 18: 798.

     OpenUrl
207. 207.
     2. Chen JA,
     3. Splenser A,
     4. Guillory B,
     5. Luo J,
     6. Mendiratta M,
     7. Belinova B, et al.

     Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015; 6: 132–3.

     OpenUrl
208. 208.
     2. Hatanaka M,
     3. Konishi M,
     4. Ishida J,
     5. Saito M,
     6. Springer J.

     Novel mechanism of ghrelin therapy for cachexia. J Cachexia Sarcopenia Muscle. 2015; 6: 393.

     OpenUrl
209. 209.↵
     2. Lundholm K,
     3. Gunnebo L,
     4. Körner U,
     5. Iresjö BM,
     6. Engström C,
     7. Hyltander A, et al.

     Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer. 2010; 116: 2044–52.

     OpenUrlCrossRefPubMed
210. 210.↵
     2. Doruk YU,
     3. Yarparvar D,
     4. Akyel YK,
     5. Gul S,
     6. Taskin AC,
     7. Yilmaz F, et al.

     A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude. J Biol Chem. 2020; 295: 3518–31.

     OpenUrlAbstract/FREE Full Text
211. 211.↵
     2. Saxton RA,
     3. Sabatini DM.

     mTOR signaling in growth, metabolism, and disease. Cell. 2017; 169: 361–71.

     OpenUrlCrossRefPubMed
212. 212.
     2. Shimobayashi M,
     3. Hall MN.

     Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014; 15: 155–62.

     OpenUrlCrossRefPubMed
213. 213.
     2. González A,
     3. Hall MN.

     Nutrient sensing and TOR signaling in yeast and mammals. EMBO J. 2017; 36: 397–408.

     OpenUrlAbstract/FREE Full Text
214. 214.↵
     2. Hay N,
     3. Sonenberg N.

     Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926–45.

     OpenUrlAbstract/FREE Full Text
215. 215.↵
     2. Matsumoto CS,
     3. Almeida LO,
     4. Guimarães DM,
     5. Martins MD,
     6. Papagerakis P,
     7. Papagerakis S, et al.

     PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget. 2016; 7: 42393–407.

     OpenUrl
216. 216.↵
     2. Bobrovnikova-Marjon E,
     3. Grigoriadou C,
     4. Pytel D,
     5. Zhang F,
     6. Ye J,
     7. Koumenis C, et al.

     PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene. 2010; 29: 3881–95.

     OpenUrlCrossRefPubMedWeb of Science
217. 217.
     2. Pytel D,
     3. Gao Y,
     4. Mackiewicz K,
     5. Katlinskaya YV,
     6. Staschke KA,
     7. Paredes MCG, et al.

     PERK is a haploinsufficient tumor suppressor: gene dose determines tumor-suppressive versus tumor promoting properties of PERK in melanoma. PLoS Genet. 2016; 12: e1006518.
218. 218.↵
     2. Bhattacharya S,
     3. HuangFu WC,
     4. Dong G,
     5. Qian J,
     6. Baker DP,
     7. Karar J, et al.

     Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene. 2013; 32: 4214–21.

     OpenUrlCrossRefPubMed
219. 219.↵
     2. Lee Y,
     3. Fong SY,
     4. Shon J,
     5. Zhang SL,
     6. Brooks R,
     7. Lahens NF, et al.

     Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle. Sci. Adv. 2021; 7: eabd2645.
220. 220.↵
     2. Isakoff MS,
     3. Bielack SS,
     4. Meltzer P,
     5. Gorlick R.

     Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015; 33: 3029–35.

     OpenUrlAbstract/FREE Full Text
221. 221.↵
     2. Tang QL,
     3. Xie XB,
     4. Wang J,
     5. Chen Q,
     6. Han AJ,
     7. Zou CY, et al.

     Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Ins. 2012; 104: 749–63.

     OpenUrlCrossRefPubMedWeb of Science
222. 222.↵
     2. Liu HC,
     3. Enikolopov G,
     4. Chen Y.

     Cul4B regulates neural progenitor cell growth. BMC Neurosci. 2012; 13: 112.

     OpenUrlCrossRefPubMed
223. 223.
     2. Soucy TA,
     3. Smith PG,
     4. Milhollen MA,
     5. Berger AJ,
     6. Gavin JM,
     7. Adhikari S, et al.

     An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009; 458: 732–6.

     OpenUrlCrossRefPubMedWeb of Science
224. 224.
     2. Nawrocki ST,
     3. Griffin P,
     4. Kelly KR,
     5. Carew JS.

     MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012; 21: 1563–73.

     OpenUrlCrossRefPubMed
225. 225.
     2. Khalife J,
     3. Radomska HS,
     4. Santhanam R,
     5. Huang X,
     6. Neviani P,
     7. Saultz J, et al.

     Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. 2015; 29: 1981–92.

     OpenUrlCrossRef
226. 226.
     2. Chen P,
     3. Hu T,
     4. Liang Y,
     5. Jiang Y,
     6. Pan Y,
     7. Li C, et al.

     Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer. Oncotarget. 2015; 6: 9002–17.

     OpenUrlCrossRefPubMed
227. 227.↵
     2. Kuo KL,
     3. Ho IL,
     4. Shi CS,
     5. Wu JT,
     6. Lin WC,
     7. Tsai YC, et al.

     MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer Lett. 2015; 363: 127–36.

     OpenUrl
228. 228.↵
     2. Zhang S,
     3. Zhang J,
     4. Deng Z,
     5. Liu H,
     6. Mao W,
     7. Jiang F, et al.

     Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells. Oncotarget. 2016; 7: 66087–99.

     OpenUrl
229. 229.↵
     2. Yu X,
     3. Rollins D,
     4. Ruhn KA,
     5. Stubblefield JJ,
     6. Green CB,
     7. Kashiwada M, et al.

     TH17 cell differentiation is regulated by the circadian clock. Science. 2013; 342: 727–30.

     OpenUrlAbstract/FREE Full Text
230. 230.↵
     2. Hand LE,
     3. Gray KJ,
     4. Dickson SH,
     5. Simpkins DA,
     6. Ray DW,
     7. Konkel JE, et al.

     Regulatory T cells confer a circadian signature on inflammatory arthritis. Nat Commun. 2020; 11: 1658.

     OpenUrl
231. 231.↵
     2. Hu X,
     3. Liu X,
     4. Moisan J,
     5. Wang Y,
     6. Lesch CA,
     7. Spooner C, et al.

     Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology. 2016; 5: e1254854.
232. 232.↵
     2. Mullins D,
     3. Proulx D,
     4. Saoudi A,
     5. Ng CE.

     Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity. Int J Radiat Oncol Biol Phys. 2005; 62: 230–7.

     OpenUrlPubMed
233. 233.↵
     2. Ozturk N,
     3. Ozturk D,
     4. Pala-Kara Z,
     5. Kaptan E,
     6. Sancar-Bas S,
     7. Ozsoy N, et al.

     The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus. Chronobiol Int. 2018; 35: 705–s18.

     OpenUrl